|
E-mail this page to a friend!
Blood Test that Beat Mammogram at Finding Breast
Cancer Moves Forward
BT Test ready to start new clinical trials this month
to prove early detection system
March 3, 2006 The BT Test, a revolutionary blood
test that in previous clinical studies has shown to significantly exceed
the accuracy of mammograms in detecting breast cancer, is ready to
launch additional clinical trials in March, according to an announcement
by Biomarker Technologies. It is hopeful news for senior citizens, since
breast cancer risk increases with age. It is the leading cause of cancer
in women, and studies have shown that early detection leads to a 97
percent, five-year survival rate.
| |
Related Stories |
|
| |
Study of Postmenopausal Women
Low-Fat Diet with Fruit, Veggies, Grains Does NOT
Reduce Heart, Breast Cancer or Colon Cancer Risks
Study findings send shock waves through health
care community
Feb. 6, 2006 Results of new studies were
released today that indicate a diet low in fat, but high in fruit,
vegetables and grains, does not significantly reduce the risk of breast
cancer, colorectal cancer or cardiovascular disease in postmenopausal
women. These findings that run counter to what has been
preached by health experts for years. The three articles will be
published in tomorrow's Journal of the American Medical Association
(JAMA), but they have already stirred up a storm of caution.
Read more...
Read more
on
Health & Medicine |
|
The upcoming study will examine women's blood for a
number of cancer related biomarkers, which are specific proteins having
concentrations that are measurably different in patients with breast
cancer. The BT Test is a first-of-its-kind blood diagnostic that detects
the presence of breast cancer at the molecular level.
"We expect the results of this clinical study to
demonstrate an even higher level of accuracy than either film or digital
mammography," said William Gartner, CEO and President of Biomarker
Technologies. "With this greatly improved diagnostic accuracy, the BT
Test will ultimately become a critical tool in detecting breast cancer
without the discomfort and inconvenience of a mammogram."
The study will involve 430 women referred for
biopsy, 125 women referred for other types of cancer, and 300 healthy
subjects.
| |
About Breast Cancer Risk |
|
| |
● The National Cancer Institute estimates that,
based on current rates, 13.2 percent of women born today will be
diagnosed with
breast
cancer at some time in their lives.
● Because rates of breast cancer increase with age, estimates
of risk at specific ages are more meaningful than estimates of
lifetime risk.
● An estimated risk represents the average risk for all women
in the United States as a group. This estimate does not indicate
the risk for an individual woman because of individual
differences in age,
family history, reproductive history, race/ethnicity, and
other factors.
● Estimated lifetime risk of breast cancer has gone up
gradually over the past several decades. This year it declined
slightly
A womans chance of being diagnosed with
breast cancer is:
● from age 30 through age 39 = 0.44 percent
(often expressed as 1 in 229)
● from age 40 through age 49 = 1.46 percent (often expressed
as 1 in 68)
● from age 50 through age 59 = 2.73 percent (often expressed
as 1 in 37)
● from age 60 through age 69 = 3.82 percent (often expressed
as 1 in 26)
More at National Cancer Institute - Click
|
|
The study is expected to take four months to
complete, with the collection of blood samples beginning in early March
2006.
Gartner said that the BT test can provide higher
sensitivity, a broader range of age applicability, and ease of
administration and patient convenience while greatly increasing the
number of early detections.
"This clinical study will move the BT Test forward
in its FDA approval as first a supplementary and then a stand-alone
screening tool for early breast cancer detection," said Gartner. "With
fewer false negative and false positive diagnoses, this cost-effective
blood test may not only offer vastly superior early-detection
capabilities in routine examinations, but may also help patients avoid
unnecessary needle biopsies."
The study will also examine using the BT Test
together with the Riboflavin Carrier Protein biomarker from RCP
Diagnostics LLC, which may enhance the sensitivity of the BT Test beyond
the expected level of accuracy.
For more information on BT Test, please visit
www.biomarkertech.com or contact Biomarker Technologies at 602-468-0067.
About Biomarker Technologies
Arizona-based Biomarker Technologies LLC (www.biomarkertech.com) is a
translational in-vitro diagnostic company focused on the diagnosis of
breast cancer. The company is poised to quickly bring the BT Test to
market either by licensing the test to a large global provider or
through FDA's ASR Reference Lab Program.
Source: Biomarker Technologies
Click here to Search SeniorJournal.com for more on
this subject
Click to More Senior News on the
Front Page
Copyright: SeniorJournal.com |
